A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186
Cameron J. Herting, Matthew R. Farren, Yan Tong, Ziyue Liu, Bert H. O’Neil, Tanios Bekaii‐Saab, Anne M. Noonan, Christopher McQuinn, Thomas A. Mace, Walid L. Shaib, Christina Wu, Bassel F. El‐Rayes, Safi Shahda, Gregory B. Lesinski
Topics & Concepts
PembrolizumabMedicineOncologyClinical endpointInternal medicineRegimenChemotherapy regimenResponse Evaluation Criteria in Solid TumorsNeutropeniaPhases of clinical researchColorectal cancerImmune systemChemotherapyImmunotherapyCancerImmunologyClinical trialCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer